EWP
IBRX icon

Elevation Wealth Partners’s ImmunityBio IBRX Stock Holding History

Elevation Wealth Partners’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Hold
1,500
– – ﹤0.01% 725
2026
Q1 		$11.5K Hold
1,500
– – ﹤0.01% 486
2025
Q4 		$2.97K Hold
1,500
– – ﹤0.01% 732
2025
Q3 		$3.69K Hold
1,500
– – ﹤0.01% 530
2025
Q2 		$3.96K Hold
1,500
– – ﹤0.01% 415
2025
Q1 		$4.51K Hold
1,500
– – ﹤0.01% 410
2024
Q4 		$3.84K Hold
1,500
– – ﹤0.01% 424
2024
Q3 		$5.58K Buy
+1,500
New +$6.94K ﹤0.01% 386

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Elevation Wealth Partners's IBRX Position: Q2 2026 in Review

Elevation Wealth Partners held its ImmunityBio (IBRX) position steady in Q2 2026 at 1,500 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #725.

Elevation Wealth Partners first reported a position in IBRX in Q3 2024 and has held it in 8 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Elevation Wealth Partners held 1,500 shares of ImmunityBio worth $13.1K as of Q2 2026.
  • Elevation Wealth Partners left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #725 holding.
  • Elevation Wealth Partners first reported a position in ImmunityBio in Q3 2024 and has held it in 8 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.